Etonogestrel implant - Merck & Co

Drug Profile

Etonogestrel implant - Merck & Co

Alternative Names: 3-Keto-desogestrel; 3-Keto-DOG; 3-Oxodesogestrel; Implanon; Implanon NXT; Nexplanon; ORG-3236

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Organon
  • Developer Pharmaco (NZ); Schering-Plough
  • Class Hormonal contraceptives; Norpregnanes; Progesterone congeners; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 09 Nov 2011 A new formulation of the etonogestrel implant has been launched as Nexplanon® for Contraception in the US
  • 19 Nov 2007 Organon has been acquired and merged into Schering-Plough
  • 18 Jul 2006 Registered for Pregnancy (Prevention) in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top